Ascendis Pharma A/S (NASDAQ:ASND) Trading Down 11.1% – Should You Sell?

Shares of Ascendis Pharma A/S (NASDAQ:ASND) dropped 11.1% on Tuesday . The company traded as low as $234.12 and last traded at $235.6050. Approximately 288,955 shares changed hands during trading, a decline of 57% from the average session volume of 667,871 shares. The stock had previously closed at $264.92.

Key Stories Impacting Ascendis Pharma A/S

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: Ascendis authorized a share repurchase program of up to $400 million. Although purchases are discretionary and may be modified or suspended, the program could support earnings per share and signal management’s confidence in the company’s financial position. Ascendis Announces Planned $400 Million Share Repurchase Program
• Positive Sentiment: Insider activity has been broadly supportive over the past six months, with nine purchases versus two sales. Institutional ownership was also mixed, but major investors including T. Rowe Price, BlackRock and State Street reported sizable additions.
• Neutral Sentiment: Ascendis will regain exclusive rights to its TransCon programs in metabolic and cardiovascular diseases, including once-monthly TransCon semaglutide for potential obesity and type 2 diabetes treatment. The move gives Ascendis greater control and potential long-term value, but the programs remain investigational and require further development, regulatory approval and funding. Ascendis to Regain Rights to TransCon Technology
• Negative Sentiment: The termination removes Novo Nordisk’s partnership support and leaves Ascendis responsible for development, manufacturing and commercialization. Investors appear concerned that Ascendis is losing near-term certainty and taking on greater execution, financial and regulatory risk.
• Negative Sentiment: A same-day Raymond James rating action reinforced the cautious reaction, even though several earlier analysts maintained bullish targets. The reported median 12-month target of approximately $326 remains above recent trading levels, but those targets may not yet fully reflect the partnership change. Raymond James Analyst Action

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ASND. Raymond James Financial lowered shares of Ascendis Pharma A/S from a “strong-buy” rating to an “outperform” rating and set a $287.00 target price for the company. in a report on Tuesday. Weiss Ratings raised shares of Ascendis Pharma A/S from a “sell (d)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. HC Wainwright set a $344.00 price target on shares of Ascendis Pharma A/S in a research report on Thursday, September 10th. Bank of America reduced their price objective on shares of Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Finally, Jefferies Financial Group decreased their price objective on shares of Ascendis Pharma A/S from $333.00 to $330.00 and set a “buy” rating on the stock in a research report on Monday, August 31st. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of “Buy” and an average price target of $310.80.

Ascendis Pharma A/S Price Performance

The firm has a 50 day moving average of $257.36 and a 200-day moving average of $242.38. The company has a market cap of $14.50 billion, a P/E ratio of 18.03 and a beta of 0.35. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.71 by ($0.68). The business had revenue of $387.22 million during the quarter, compared to the consensus estimate of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. On average, equities research analysts predict that Ascendis Pharma A/S will post 3.69 EPS for the current year.

Insider Transactions at Ascendis Pharma A/S

In other news, Director Jean-Jacques Bienaimé bought 2,000 shares of Ascendis Pharma A/S stock in a transaction dated Friday, August 14th. The shares were purchased at an average cost of $246.33 per share, with a total value of $492,660.00. Following the completion of the acquisition, the director owned 2,900 shares of the company’s stock, valued at $714,357. This trade represents a 222.22% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Mads Bodenhoff sold 3,000 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the transaction, the senior vice president directly owned 3,000 shares of the company’s stock, valued at approximately $810,570. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 40.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Leonteq Securities AG purchased a new position in Ascendis Pharma A/S during the 4th quarter worth $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in Ascendis Pharma A/S in the fourth quarter valued at about $42,000. EverSource Wealth Advisors LLC raised its stake in Ascendis Pharma A/S by 34.0% in the first quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 69 shares during the last quarter. Allworth Financial LP raised its stake in Ascendis Pharma A/S by 103.4% in the second quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 122 shares during the last quarter. Finally, Parallel Advisors LLC boosted its holdings in Ascendis Pharma A/S by 94.9% in the first quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock worth $70,000 after acquiring an additional 148 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve the effectiveness, convenience, and tolerability of established treatments.

Ascendis’ marketed products include Skytrofa (lonapegsomatropin-tcgd), a long-acting growth hormone approved for the treatment of growth hormone deficiency in children, and Yorvipath (palopegteriparatide), a hormone replacement therapy for adults with hypoparathyroidism.